[Source](https://github.com/mm80843/T3.5/blob/main/docs/index.md) -- [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) 

# Benef: __Thorough study of anti-coronavirus drugs__ (PBN__Benef_64)

## Property: has_Beneficiary

* [researchers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_2.md)
* [scientists](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_46.md)

## Property: has_BenefSource

* [he_cido_2020](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_13.md)

## Property: has_BenefReturn

* [Private investors can benefit indirectly from the improved understanding and analysis of anti-coronavirus drugs, potentially leading to better-targeted and more effective treatments, attracting investment and commercial interest.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_64.md)

## Property: has_BenefDetails

Ontological representation of missing drug information enables comprehensive study and analysis of anti-coronavirus drugs, aiding in the design of effective treatments.

